TCL Archive National Action Plan: Return $14 Million To NCI, Committee Tells Shalala February 14, 1997
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive NSABP Submits Appeal To NIH To Reverse Cancellation Of P-4 Chemoprevention Trial. August 10, 2007
TCL Archive NCI Clinical Research Too Similar To Work By Extramural Community, Report Finds July 21, 1995
